Home World News GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of... World News GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes By Ogkologos - July 13, 2026 176 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large real-world cohort Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... November 29, 2023 Cancer Research UK’s Race for Life celebrates its 30th year by... April 24, 2023 New Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of... January 26, 2023 Load more HOT NEWS Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced... Why Keeping Up With Your Cancer Screening Is So Important Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... Can Artificial Intelligence Help See Cancer in New, and Better, Ways?
